Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 9,794 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Advanced Cancer Clear all
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

NCT07751042
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
STX-003, KEYTRUDA®
Biological
Lead sponsor
Strand Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

NCT01387555
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions
JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Biological · Other
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
La Jolla, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT00016185
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

NCT00257608
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, placebo, erlotinib HCl
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
177
States / cities
Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 21, 2026, 5:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

NCT06470750
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 3 Interventional Results available

Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer

NCT00699374
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
sunitinib malate, sorafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,075 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
35
States / cities
Fountain Valley, California • La Jolla, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer

NCT00080418
View directory record Official record
Conditions
Neoplasm
Interventions
Liposome Entrapped Paclitaxel Easy to Use
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
3
States / cities
Tampa, Florida • New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors

NCT00080990
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, fluorouracil, oxaliplatin, leucovorin calcium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

NCT02771626
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
Interventions
CB-839, Nivolumab
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1Phase 2 Interventional

Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

NCT00003585
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin, recombinant interferon alfa, fluorouracil, isotretinoin, surgical procedure
Biological · Drug · Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional Results available

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785
View directory record Official record
Conditions
Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
Interventions
Niraparib, TSR-042, Carboplatin-Paclitaxel, Bevacizumab, TSR-022, Carboplatin-Pemetrexed, Carboplatin-Nab-Paclitaxel
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
8
States / cities
Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 21, 2026, 5:21 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed No phase listed Observational

Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy

NCT01869218
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 1 Interventional

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

NCT06391918
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
GEN2 + Valganciclovir
Biological
Lead sponsor
GenVivo, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 1 Interventional Results available

ECI301 and Radiation for Advanced or Metastatic Cancer

NCT01441115
View directory record Official record
Conditions
Cancer, Neoplasm Metastasis, Radiation Oncology, Neoplasm, Metastasis
Interventions
Radiation Therapy, ECI301
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 1 Interventional

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

NCT04025216
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma
Interventions
CART-TnMUC1, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1Phase 2 Interventional

A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma

NCT00304525
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RAF265
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Augusta, Georgia • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 2 Interventional

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

NCT00095693
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage III Follicular Thyroid Cancer, Stage III Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
Interventions
sorafenib tosylate, laboratory biomarker analysis, pharmacological study, fludeoxyglucose F 18, positron emission tomography, dynamic contrast-enhanced magnetic resonance imaging
Drug · Other · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 21, 2026, 5:21 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Panitumumab/Cisplatin/Fluorouracil Combined With Radiation in Esophageal Cancer

NCT01128387
View directory record Official record
Conditions
Cancer
Interventions
Panitumumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies

NCT00890955
View directory record Official record
Conditions
Lung Cancer
Interventions
Amrubicin, Cyclophosphamide
Drug
Lead sponsor
Lawrence Einhorn
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Springdale, Arkansas • Newark, Delaware • Galesburg, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1Phase 2 Interventional

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

NCT03543189
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT03403049
View directory record Official record
Conditions
Pancreatic Cancer, Cancer
Interventions
Carbon Ion, Gemcitabine + Cisplatin, Gemcitabine + Capecitabine, Gemcitabine + Erlotinib, Gemcitabine, Photon
Radiation · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 5:21 PM EDT
Completed Phase 1 Interventional

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

NCT00091585
View directory record Official record
Conditions
Neoplasms
Interventions
SNS-595
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2007 · Synced Oct 21, 2026, 5:21 PM EDT
Active, not recruiting Phase 1 Interventional

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

NCT05239143
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
Interventions
P-MUC1C-ALLO1 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2039
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 21, 2026, 5:21 PM EDT